Lavipharm has entered into a cooperation agreement with the Belgian medical plant specialist Tilman in the sector of plant based pharmaceutical products. Tilman is one of the largest companies in Europe and its plant originated products are marketed in 30 countries around the world. Tilman laboratories, established 50 years...
In this environment, Lavipharm mainly focused on the enhancement of its export activities. At the same time, despite the constant twists and instability that prevailed and obstructed the business plans, the Company followed a long-term plan to boost sales in the domestic market and to...
In a difficult financial environment, with constant changes in the legal framework of the health sector, and especially in pharmaceuticals, Lavipharm has further strengthened its extrovert activities, aiming to an even greater growth of exports. At the same time, the company implemented its long-term plan to...
In this environment, the consolidated turnover of Lavipharm reached 198.4 million Euros compared to 249.8 million Euros for the corresponding period in 2009. Due to the fall of pharmaceuticals' prices, Gross profit dropped to 31.7 million Euros from 39.5 million Euros in 2009. In Lavipharm,...
The turmoil created in the Greek pharmaceutical market since the beginning of the year has seriously affected the turnover of pharmaceutical companies. The anticipation of price changes announced by the government at the beginning of the year and implemented consecutively in June and September, led...
In the context of the ASE regulations and under the 3/347/12.07.05 Board Resolution of Hellenic Capital Market Commission, Lavipharm advises that Mr. Ioannis Alexiades assumes the responsibility of Internal Auditor replacing Mr. Georgios Gemelos....
During the first semester of 2010, turmoil was created in the Greek pharmaceutical market, in anticipation of price reductions which were announced by the government at the beginning of the year but were implemented early June. Although, according to IMS data, sales of medicines from...
The turmoil created in the pharmaceuticals' market during the first quarter of 2010 -which continues until today- has significantly affected Lavipharm's Financials. In anticipation of the decrease in drug prices, as expected since the beginning of the year, sales have dropped drastically, due to warehouses...
Consolidated Turnover posted an increase of 5%, reaching Euro 249.8 million compared to Euro 238.0 million during 2008. International Sales have increased by 17%, accounting for 11% of Total Sales. Gross Profit reached Euro 39.5 million from Euro 37.4 million in the last period (+5.6%)....
Profitability and constant growth highlight Lavipharm Group financial results of 9M 2009, maintaining its positive course since the beginning of the year. Consolidated Turnover reached Euro 182,9 million compared to Euro 176,4 million during the 9M of 2008. The significant decrease in operating expenses (-14,9%)...
